Concord Biotech Limited IPO
MainboardPharmaceuticals
Listed On: Aug 18, 2023 at ₹ 900.05(NSE)
₹ 14820 /20 Shares
Check AllotmentPrice Summary
Last Closing
2,030.10 (173.97%)52 Week High
2,664.0052 Week Low
1,221.00Last Update
22-Nov-2024 3:30 PMConcord Biotech Limited IPO Details
04 Aug, 2023
Open Date08 Aug, 2023
Close Date11 Aug, 2023
Allotment Date18 Aug, 2023
Listing DateIssue Price
₹705-741 per equity shareFace Value
₹1 Per Equity ShareListing at Group
BSE, NSERegistrar
Link Intime India Private LimitedList Price
900.05(NSE)Listing Date
2023-08-18Market Lot
Retail : 20 Shares (₹14,820/-)S-HNI : 280 Shares (₹2,07,480/-)
B-HNI : 1,360 Shares (₹10,07,760/-)
Lead Manager
Kotak Mahindra Capital Company LimitedCitigroup Global Markets India Private Limited
Jefferies India Private Limited
Issue Size
Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr)Retail Portion
35% (Number of Retail Applications: 3,66,024 Approx),(Number of S-HNI Applications : 3,735 Approx),
(Number of B-HNI Applications : 7,470 Approx)
Subscription
24.86 timesConcord Biotech Limited IPO Subscription Details
As on | QIB | NII bNII sNII | Retail | Employee | Total |
---|---|---|---|---|---|
Shares Offered / Reserved | 4,183,130 | 3,137,348 2,091,565 1,045,783 | 7,320,479 | 10,000 | 14,650,957 |
Day 1 - 04-08-23 05:00 PM | 0.01 x | 1.01 0.96 x 1.11 x | 0.72 x | 5.73 x | 0.58 x |
Day 2 - 07-08-23 05:00 PM | 1.61 x | 5.22 5.12 x 5.42 x | 2.26 x | 15.68 x | 2.72 x |
Day 3 - 08-08-23 05:00 PM | 67.67 x | 16.99 19.30 x 12.36 x | 3.77 x | 24.39 x | 24.86 x |
Concord Biotech Limited Valuations
Earnings Per Share (EPS)
₹22.95/-P/E Ratio
32.3RoNW
20.06%Net Asset Value (NAV) - As on 31.03.23
₹123.3Concord Biotech Limited Company Financials All values are in ₹ Cr.
31-Mar-23 | 31-Mar-22 | 31-Mar-21 | |
---|---|---|---|
Assets | 1,513.98 | 1,312.80 | 1,182.55 |
Revenue | 888.48 | 736.35 | 630.75 |
Profit After Tax | 240.08 | 174.93 | 234.89 |
About The Company
Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.
The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.
Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.
Concord Biotech Limited - Peers Comparison
P/B Ratio | P/E Ratio | RoNW | Net Worth | |
---|---|---|---|---|
Concord Biotech | 6.01 | 32.3 | 20.06% | 888 |
Divi's Lab | 7.77 | 54.4 | 14.9% | 7,768 |
Suven Pharma | 7.25 | 30.6 | 25.2% | 1,340 |
Laurus Labs | 4.49 | 33.6 | 20.4% | 5,386 |
Concord Biotech Limited - Promoter(s)
Pre Issue Share Holding: 44.08%
Post Issue Share Holding: 44.08%
Company Promoter(s)
- Mr. Sudhir Vaid
- Mr. Ankur Vaid
Concord Biotech Limited IPO - Issue Objectives
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
- Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.
Concord Biotech Limited IPO - Anchor Investors
The government of Singapore, Abu Dhabi Investment Authority, Government Pension Fund Global, Polar Capital Funds, HSBC Mutual Fund, WF Asian Reconnaissance Fund, Amundi Funds, The Prudential Assurance Company and Pinebridge Global Funds are the marquee investors that participated in the anchor book of the professionally-managed biotech firm.
Apart from that, Nippon Life, UTI Mutual Fund, DSP Mutual Fund, Franklin Mutual Fund, SBI Life Insurance, Motilal Oswal Mutual Fund, Edelweiss Trusteeship, Invesco India, Bandhan Mutual Fund, Aditya Birla Sun Life, Max Life Insurance and Tata AIA Life Insurance also invested in the company via anchor book.
Concord Biotech Limited IPO - FAQs
Ans. Concord Biotech Limited IPO is a Mainboard IPO. The issue is priced at ₹705-741 per equity share. The minimum order quantity is 20 Shares. The IPO opens on Aug 4, 2023, and closes on Aug 8, 2023. Link Intime India Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Ans. The Concord Biotech Limited IPO opens on Aug 4, 2023 and closes on Aug 8, 2023.
Ans. The size of Concord Biotech Limited IPO is Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr).
Ans. The IPO price band is set between ₹705-741 per equity share.
Ans. To apply for Concord Biotech Limited IPO IPO, follow the steps given below:
- - Open the IPO Ji App or Website
- - Find Concord Biotech Limited IPO in the List of IPOs
- - Press "Apply" Button
- - Select Your Demat Account
- - Select Your Shares Quantity and Submit
- - Track Your IPO Status
Ans. The share allotment date of Concord Biotech Limited IPO is Aug 11, 2023.
Ans. The Concord Biotech Limited IPO will be listed on Aug 18, 2023.
Ans. Follow the steps to check the allotment status for Concord Biotech Limited IPO here.